Advertisement

45-Year-Old Man with Leg Pain and Numbness

Chapter
  • 358 Downloads

Abstract

Asymmetric and rapidly progressive painful sensorimotor disturbances raise concern for vasculitic neuropathy, the most common cause of which is non-systemic vasculitic neuropathy (NSVN). Nerve damage occurs by ischemic injury via mechanisms that differ between each process. The diagnosis is confirmed by history, examination, electrodiagnostic studies, laboratory findings, and likely nerve/muscle biopsy. Treatment is dependent on the underlying cause, and diagnosis is focused on evaluation for systemic vasculitides that can result in significant morbidity. In the case of NSVN, corticosteroids and consideration of other immunosuppressants are necessary to avoid further injury and disability.

Keywords

Vasculitis Neuropathy Non-systemic vasculitic neuropathy Mononeuritis multiplex 

References

  1. 1.
    Reife MD, Coulis CM. Peroneal neuropathy misdiagnosed as L5 radiculopathy: a case report. Chiropr Man Therap. 2013;21(1):12.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Collins MP, Periquet MI. Isolated vasculitis of the peripheral nervous system. Clin Exp Rheumatol. 2008;26(3):S118–30.PubMedGoogle Scholar
  3. 3.
    Kararizou E, Davaki P, Karandreas N, Davou R, Vassilopoulos D. Nonsystemic vasculitic neuropathy: a clinicopathological study of 22 cases. J Rheumatol. 2005;32(5):853–8.PubMedGoogle Scholar
  4. 4.
    Bennett DL, Groves M, Blake J, Holton JL, King RHM, Orrell RW, et al. The use of nerve and muscle biopsy in the diagnosis of vasculitis: a 5 year retrospective study. J Neurol Neurosurg Psychiatry. 2008;79(12):1376–81.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Collins MP, Arnold WD, Kissel JT. The neuropathies of vasculitis. Neurol Clin. 2013;31(2):557–95.PubMedCrossRefGoogle Scholar
  6. 6.
    Takahashi M, Koike H, Ikeda S, Kawagashira Y, Iijima M, Hashizume A, et al. Distinct pathogenesis in nonsystemic vasculitic neuropathy and microscopic polyangiitis. Neurol Neuroimmunol Neuroinflamm. 2017;4(6):e407.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Morozumi S, Koike H, Tomita M, Kawagashira Y, Iijima M, Katsuno M, et al. Spatial distribution of nerve fiber pathology and vasculitis in microscopic polyangiitis-associated neuropathy. J Neuropathol Exp Neurol. 2011;70(5):340–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Ntatsaki E, Carruthers D, Chakravarty K, D'Cruz D, Harper L, Jayne D, et al. BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford). 2014;53(12):2306–9.CrossRefGoogle Scholar
  9. 9.
    Waldfogel JM, Nesbit SA, Dy SM, Sharma R, Zhang A, Wilson LM, et al. Pharmacotherapy for diabetic peripheral neuropathy pain and quality of life: a systematic review. Neurology. 2017;88(20):1958–67.PubMedCrossRefGoogle Scholar
  10. 10.
    Bril V, England J, Franklin GM, Backonja M, Cohen J, Del Toro D, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PM R. 2011;3(4):345–52, 52.e1–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88.PubMedCrossRefGoogle Scholar
  12. 12.
    De Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis. 2007;39:S122–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. Nat Rev Neurol. 2017;13(5):302–16.PubMedCrossRefGoogle Scholar
  14. 14.
    Collins MP, Periquet MI, Mendell JR, Sahenk Z, Nagaraja HN, Kissel JT. Nonsystemic vasculitic neuropathy: insights from a clinical cohort. Neurology. 2003;61(5):623–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Uceyler N, Geng A, Reiners K, Toyka KV, Sommer C. Non-systemic vasculitic neuropathy: single-center follow-up of 60 patients. J Neurol. 2015;262(9):2092–100.PubMedCrossRefGoogle Scholar
  16. 16.
    Gonzalez-Gay MA, Garcia-Porrua C. Systemic vasculitis in adults in northwestern Spain, 1988-1997. Clinical and epidemiologic aspects. Medicine (Baltimore). 1999;78(5):292–308.CrossRefGoogle Scholar
  17. 17.
    Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener’s granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004;51(1):92–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Pagnoux C, Seror R, Henegar C, Mahr A, Cohen P, Le Guern V, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum. 2010;62(2):616–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Terrier B, Lacroix C, Guillevin L, Hatron PY, Dhote R, Maillot F, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjogren's syndrome-related neuropathy. Arthritis Rheum. 2007;57(8):1520–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Zivkovic SA, Ascherman D, Lacomis D. Vasculitic neuropathy – electrodiagnostic findings and association with malignancies. Acta Neurol Scand. 2007;115(6):432–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Deprez M, de Groote CC, Gollogly L, Reznik M, Martin JJ. Clinical and neuropathological parameters affecting the diagnostic yield of nerve biopsy. Neuromuscul Disord. 2000;10(2):92–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Lindenlaub T, Sommer C. Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol. 2003;105(6):593–602.PubMedCrossRefGoogle Scholar
  23. 23.
    Vrancken AF, Notermans NC, Jansen GH, Wokke JH, Said G. Progressive idiopathic axonal neuropathy – a comparative clinical and histopathological study with vasculitic neuropathy. J Neurol. 2004;251(3):269–78.PubMedCrossRefGoogle Scholar
  24. 24.
    Collins MP, Dyck PJ, Gronseth GS, Guillevin L, Hadden RD, Heuss D, et al. Peripheral nerve society guideline on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. J Periph Nerv Syst. 2010;15(3):176–84.CrossRefGoogle Scholar
  25. 25.
    Collins MP, Mendell JR, Periquet MI, Sahenk Z, Amato AA, Gronseth GS, et al. Superficial peroneal nerve/peroneus brevis muscle biopsy in vasculitic neuropathy. Neurology. 2000;55(5):636–43.PubMedCrossRefGoogle Scholar
  26. 26.
    Rappaport WD, Valente J, Hunter GC, Rance NE, Lick S, Lewis T, et al. Clinical utilization and complications of sural nerve biopsy. Am J Surg. 1993;166(3):252–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Hadden RDM, Collins MP, Zivkovic SA, Hsieh ST, Bonetto C, Felicetti P, et al. Vasculitic peripheral neuropathy: case definition and guidelines for collection, analysis, and presentation of immunisation safety data. Vaccine. 2017;35(11):1567–78.PubMedCrossRefGoogle Scholar
  28. 28.
    Vrancken AF, Hughes RA, Said G, Wokke JH, Notermans NC. Immunosuppressive treatment for non-systemic vasculitic neuropathy. Cochrane Database Syst Rev. 2007;(24):1.Google Scholar
  29. 29.
    Pollard JD, McLeod JG, Spies JM, Davies L. Vasculitis confined to peripheral nerves. Brain. 1996;119(5):1441–8.PubMedCrossRefGoogle Scholar
  30. 30.
    Collins MP. The vasculitic neuropathies: an update. Curr Opin Neurol. 2012;25(5):573–85.PubMedCrossRefGoogle Scholar
  31. 31.
    Gwathmey KG, Burns TM, Collins MP, Dyck PJ. Vasculitic neuropathies. Lancet Neurol. 2014;13(1):67–82.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Vermont Medical CenterBurlingtonUSA
  2. 2.Department of NeurosciencesUniversity of Vermont Medical CenterBurlingtonUSA

Personalised recommendations